Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 3/20 | 0.69 |
| ▸ | CYP11B2 | P19099 | 6/20 | 0.64 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.64 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.57 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | BCL2 | P10415 | 1/20 | 0.40 |
| ▸ | FGF23 | Q9GZV9 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22569104 | 0.91 | PTGS2 (0.63) | PTGS2CYP11B2CYP11B1CYP19A1MAOA | |
| SCHEMBL22568906 | 0.91 | PTGS2 (0.62) | PTGS2CYP11B2CYP11B1CYP19A1MAOA | |
| SCHEMBL9054140 | 0.90 | PTGS2 (0.78) | PTGS2CYP11B2CYP11B1CYP19A1MAOA | |
| SCHEMBL22568913 | 0.88 | PTGS2 (0.62) | PTGS2CYP11B2CYP11B1CYP19A1MAOA | |
| SCHEMBL22568915 | 0.87 | PTGS2 (0.62) | PTGS2CYP11B2CYP11B1CYP19A1MAOA | |
| SCHEMBL4127673 | 0.87 | PTGS2 (0.65) | PTGS2CYP11B2CYP11B1CYP19A1MAOA | |
| SCHEMBL22568905 | 0.84 | PTGS2 (0.50) | PTGS2CYP11B2CYP11B1CYP19A1ESR1 | |
| SCHEMBL225239 | 0.81 | PTGS2 (0.51) | PTGS2CYP11B2CYP11B1CYP19A1MAOA | |
| SCHEMBL30952382 | 0.81 | CYP11B2 (0.73) | PTGS2CYP11B2CYP11B1CYP19A1MAOA | |
| SCHEMBL22568904 | 0.81 | CYP11B2 (0.73) | PTGS2CYP11B2CYP11B1CYP19A1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2200962-A1 | BENZOCYCLOHEPTENE DERIVATIVES AS ESTROGENS HAVING SELECTIVE ACTIVITY | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-06-30 | — | — | EP | disclosed |
| US-20090099250-A1 | BENZOCYCLOHEPTENE DERIVATIVES AS ESTROGENS HAVING SELECTIVE ACTIVITY | BAYER SCHERING PHARMA AG (DE) | 2009-04-16 | — | — | US | disclosed |
| WO-2009047343-A1 | BENZOCYCLOHEPTENE DERIVATIVES AS ESTROGENS HAVING SELECTIVE ACTIVITY | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099250-A1 | BENZOCYCLOHEPTENE DERIVATIVES AS ESTROGENS HAVING SELECTIVE ACTIVITY | CYP19A1, HSD17B11, CYP21A2 | PTGS2 1642/4885CYP11B2 49/4885CYP11B1 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.